Healthy Volunteer Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-12-04

Study Completion Date

2026-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Double Blinded Healthy Volunteer study evaluating D-2570 against placebo in various doses.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Safety, Tolerability, and Pharmacokinetic Study of GDC-3280 in Healthy Participants

NCT02471859

Healthy Volunteer

COMPLETED PHASE1

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of FB825 in Healthy Volunteers

NCT02309762

Healthy

COMPLETED PHASE1

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Healthy Volunteers

NCT02596399

Healthy Volunteer

COMPLETED PHASE1

A Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Single Doses of Q203 in Normal, Healthy, Male and Female Volunteers

NCT02530710

Healthy Volunteers

COMPLETED PHASE1

Phase 1 Study(Additional) of URC102 in Healthy Subjects

NCT02524678

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Double blind study evaluating the safety, tolerability and PK data of D-2570/placebo in healthy volunteers.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1 D-2570/Placebo

Group Type EXPERIMENTAL

D-2570

Intervention Type DRUG

D-2570

Placebo

Intervention Type DRUG

Placebo

Cohort 2 D-2570/Placebo

Group Type EXPERIMENTAL

D-2570

Intervention Type DRUG

D-2570

Placebo

Intervention Type DRUG

Placebo

Cohort 3 D-2570/Placebo

Group Type EXPERIMENTAL

D-2570

Intervention Type DRUG

D-2570

Placebo

Intervention Type DRUG

Placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

D-2570

Intervention Type DRUG

Placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy volunteer subjects meeting eligibility criteria

Exclusion Criteria

* Subjects with ongoing or history of disease or co-morbidities as assessed by Principal Investigator which would make them ineligible for the study
* Subjects with a history of drug and alcohol abuse
* Subjects taking medications, over the counter or herbal remedies

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes